Serial cardiac biomarkers for risk stratification of patients with COVID-19

Several studies have demonstrated an association between elevated cardiac biomarkers and adverse outcomes in patients with COVID-19. However, the prognostic and predictive capability of a multimarker panel in a prospectively collected, diverse “all-comers” COVID-19 population has not been fully elucidated. We prospectively assessed high sensitivity cardiac troponin I (hsTnI), NT-pro B-type Natriuretic Peptide (NT-proBNP), Galectin-3 (Gal-3), and procalcitonin (PCT) in 4,282 serial samples from 358 patients admitted with symptomatic, RT-PCR confirmed SARS-CoV-2 infection. Outcomes examined were 30-day in-hospital mortality and requirement for intubation within 10 days. Baseline hsTnI had the highest AUC for predicting 30-day mortality (0.81; 95% CI, 0.73–0.88), followed by NT-proBNP (0.80; 0.74–0.86), PCT (0.77; 0.70–0.84), and Gal-3 (0.68; 0.60–0.76). HsTnI